HAMPTON, N.J., Feb. 13, 2017 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today upcoming investor events for February and March.
Upcoming Investor Conferences
Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in presentations at the following conferences:
- Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 9:30 a.m. EST in New York – fireside chat
- Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 9:20 a.m. EST in Boston – corporate presentation
Live webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentations will be available for seven days following each event.
2016 Year-End Results and Conference Call/Webcast
- Celldex will release fourth quarter and year-end 2016 financial results on Tuesday, March 14, 2017 after the U.S. financial markets close.
- Celldex will host a conference call/webcast at 4:30 p.m. EDT on the same day to provide an in-depth update on its pipeline and upcoming milestones for 2017.
Event details, including conference call phone numbers, can be accessed on the "Events & Presentations" page under the "Investors & Media" section of the Celldex website.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Associate Director of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected]


TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 



